Group Walters Purchases 6,459,973 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) major shareholder Group Walters bought 6,459,973 shares of the stock in a transaction on Wednesday, December 31st. The stock was purchased at an average price of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the purchase, the insider directly owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Zentalis Pharmaceuticals Trading Up 17.4%

Shares of NASDAQ ZNTL traded up $0.42 during midday trading on Thursday, hitting $2.84. 6,927,020 shares of the company’s stock were exchanged, compared to its average volume of 4,316,173. The business’s fifty day moving average price is $1.40 and its two-hundred day moving average price is $1.47. The company has a market cap of $205.19 million, a price-to-earnings ratio of -1.37 and a beta of 1.75. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $3.06.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.12. Equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Zentalis Pharmaceuticals by 31.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company’s stock worth $1,092,000 after acquiring an additional 172,628 shares in the last quarter. XTX Topco Ltd boosted its stake in Zentalis Pharmaceuticals by 107.2% in the 3rd quarter. XTX Topco Ltd now owns 548,629 shares of the company’s stock worth $828,000 after purchasing an additional 283,800 shares in the last quarter. Voleon Capital Management LP purchased a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000. Qube Research & Technologies Ltd grew its position in Zentalis Pharmaceuticals by 76.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 56,639 shares of the company’s stock worth $86,000 after purchasing an additional 24,526 shares during the period. Finally, Bank of America Corp DE increased its holdings in Zentalis Pharmaceuticals by 117.1% in the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ZNTL shares. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley cut their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Leerink Partners reissued a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.53.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.